The Goldman Sachs Group Cuts uniQure (NASDAQ:QURE) Price Target to $9.00

uniQure (NASDAQ:QURE) had its price target lowered by research analysts at The Goldman Sachs Group from $10.00 to $9.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 21.13% from the stock’s previous close.

Several other brokerages have also issued reports on QURE. Royal Bank of Canada dropped their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday. StockNews.com raised uniQure to a “sell” rating in a report on Thursday, October 17th. Raymond James reissued an “outperform” rating and set a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price target on shares of uniQure in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Stock Performance

Shares of QURE stock opened at $7.43 on Wednesday. The stock’s 50-day moving average is $5.73 and its two-hundred day moving average is $5.80. The firm has a market cap of $361.84 million, a price-to-earnings ratio of -1.25 and a beta of 0.90. uniQure has a 1 year low of $3.73 and a 1 year high of $11.35. The company has a debt-to-equity ratio of 1.06, a quick ratio of 7.36 and a current ratio of 7.36.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. Analysts predict that uniQure will post -4.1 earnings per share for the current year.

Institutional Investors Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc acquired a new stake in uniQure in the third quarter valued at about $53,000. Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in uniQure in the second quarter valued at about $74,000. Finally, SG Americas Securities LLC acquired a new stake in uniQure in the second quarter valued at about $79,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.